Genovate Biotechnology Co., Ltd. (TPEX:4130)
Taiwan
· Delayed Price · Currency is TWD 32.50
-2.10 (-6.07%)
Mar 9, 2026, 1:30 PM CST
Genovate Biotechnology Revenue
In the year 2025, Genovate Biotechnology had annual revenue of 492.41M TWD, down -3.61%. Genovate Biotechnology had revenue of 119.40M in the quarter ending December 31, 2025, with 1.00% growth.
Revenue
492.41M
Revenue Growth
-3.61%
P/S Ratio
7.51
Revenue / Employee
2.54M
Employees
194
Market Cap
3.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 492.41M | -18.45M | -3.61% |
| Dec 31, 2024 | 510.86M | -17.66M | -3.34% |
| Dec 31, 2023 | 528.51M | 89.75M | 20.46% |
| Dec 31, 2022 | 438.76M | 4.51M | 1.04% |
| Dec 31, 2021 | 434.25M | -38.47M | -8.14% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Formosa Pharmaceuticals | 12.16M |
| ACRO Biomedical | 36.50M |
| Energenesis Biomedical CO.,LTD. | 7.46M |
| Medigen Biotechnology | 1.59B |
| Sagittarius Life Science | 424.44M |
| BRIM Biotechnology | 3.17M |
| BioGend Therapeutics | 222.34M |
| Intech Biopharm | 113.85M |